Chong‐Rui Xu

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014 · 2K citations

Lux-lung 6, Medicine, Randomised Phase 3 +8

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu et al. · OncoImmunology · 2017 · 433 citations · Full text

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Y.S. Li, Bo Jiang, Jin‐Ji Yang et al. · Annals of Oncology · 2018 · 328 citations · Full text

Cancer Research, Unique Genetic Profiles, Oncology +11

HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers

Bob T. Li, Flavia Michelini, Sandra Misale et al. · Cancer Discovery · 2020 · 274 citations · Full text

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Hao Sun, Si‐Yang Maggie Liu, Jiaying Zhou et al. · EBioMedicine · 2020 · 245 citations · Full text